持续释放的微球 循环德克斯-复合物使用青草银曼南水凝:植物营养素输送的绿色方法
Umesh Kannamangalam Vijayan1, Aswadh Krishna2, Prasanth Shanmughan1
1R&D Centre, Akay Natural Ingredients, Kochi, Kerala 683561, India.
ACS omega
|August 26, 2024
概括
我们使用环德和花银曼南开发了稳定,可溶的转白 (t-RES) 微球. 这种天然的食品级配方为营养应用提供了t-RES的持续释放.
科学领域:
- 食品科学与技术 食品科学与技术
- 材料科学 材料科学 材料科学
- 营养保健品 营养保健品
背景情况:
- 越来越复杂的食品矩阵与有益于健康的植物营养素.
- 需要稳定和生物可用的传递系统,用于像转白醇 (t-RES) 这样的化合物.
研究的目的:
- 准备,描述和评估可溶和稳定的t-RES.微球的功能应用.
- 通过绿色,以水为基础的工艺实现t-RES的持续释放.
- 开发一个食品级,清洁标签的t-RES.交付系统.
主要方法:
- 使用马-马- (γ-CD) 形成环极-复合物 (CD-R).
- 通过凝阶段分散,将CD-R封装在青草银曼南 (FG) 水凝中,形成FG-CD-R.
- 使用PXRD,DSC,SEM,FTIR,NMR,粒子大小分析和泽塔电位测量进行表征.
- 在体外释放研究和加速稳定性测试.
主要成果:
- γ-CD形成了一个稳定的包容复合物 (CD-R),可溶性提高49倍.
- 结果FG-CD-R产生了一种无形粉末,具有持续的白醇释放.
- FG-CD-R产生了稳定的立方体结构 (500 ± 53 nm),其泽塔电位为-52 ± 5.3 mV.
- 加速研究表明,保质期为两年.
- FG-CD-R适用于具有改进感官属性的透明皮.
结论:
- FG-CD-R为t-RES提供了一个简单,可扩展,持续释放的配方.
- 该配方符合天然,食品级和清洁标签要求 (非转基因,无过敏原,素食主义者,无溶剂).
- 这项技术增强了t-RES在营养产品中的应用.
更多相关视频
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
01:19Modified-Release Drug Delivery Systems: Overview
236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236
01:30Modified-Release Drug Delivery Systems: Bioavailability
170
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
170
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
257
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
257
01:24Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
01:26Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308